Clinical trials: Squamous Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally.
- Trial name
- MarsLight-11 (NCT07217301)
- Testing
- TAK-928, Control Arm
- Where
- 50 sites in United States, China and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
- Trial name
- TeLuRide-008 (NCT07365319)
- Testing
- EIK1001, Pembrolizumab (KEYTRUDA®), Paclitaxel + Carboplatin
- Where
- 42 sites in United States, Australia and 9 more
- Volunteers
- 750 people
- Sponsor
- Eikon Therapeutics
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver.
- Trial name
- NCT03468426
- Testing
- BI 836880, Ezabenlimab
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 252 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Carcinoma, Non-small Cell Lung, Lung Cancer
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
PURPOSE: This trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and radiation therapy for patients with locally advanced Non-Small Cell Lung Cancer (NSCLC) with no prior…
- Trial name
- NCT00093132
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Agennix
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06870487
- Testing
- PF-08046032, Sasanlimab
- Where
- 4 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876…
- Conditions
- Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
- Trial name
- NCT04881045
- Testing
- PF-07257876
- Where
- 43 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Pfizer
Non-Squamous Non-Small Cell Lung Cancer
An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer
This study will evaluate the anti-tumour activity, safety and tolerability of RO4929097 as monotherapy in patients with recurrent or refractory non-small cell lung cancer.
- Trial name
- NCT01070927
- Testing
- RO4929097
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors Cancer
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as…
- Trial name
- NCT02955251
- Testing
- ABBV-428, Nivolumab
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 61 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer, Cutaneous Melanoma
RTX-224 Monotherapy in Patients With Solid Tumors
This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT05219578
- Testing
- RTX-224
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rubius Therapeutics
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Lung Cancer
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003562
- Testing
- carboplatin, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Hope Cancer Institute, Inc.
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer)
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are…
- Conditions
- Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
- Trial name
- NCT05873686
- Testing
- NXP900
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Nuvectis Pharma, Inc.
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed…
- Conditions
- Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
- Trial name
- NCT06735391
- Testing
- JMT101, Osimertinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals